19 February 2024 in Nature Methods
The human bone marrow (BM) niche sustains hematopoiesis throughout life. We present a method for generating complex BM-like organoids (BMOs) from human induced pluripotent stem cells (iPSCs). BMOs consist of key cell types that self-organize into spatially defined three-dimensional structures mimicking cellular, structural and molecular characteristics of the hematopoietic microenvironment. Functional properties of BMOs include the presence of an in vivo-like vascular network, the presence of multipotent mesenchymal stem/progenitor cells, the support of neutrophil differentiation and responsiveness to inflammatory stimuli. Single-cell RNA sequencing revealed a heterocellular composition including the presence of a hematopoietic stem/progenitor (HSPC) cluster expressing genes of fetal HSCs. BMO-derived HSPCs also exhibited lymphoid potential and a subset demonstrated transient engraftment potential upon xenotransplantation in mice. We show that the BMOs could enable the modeling of hematopoietic developmental aspects and inborn errors of hematopoiesis, as shown for human VPS45 deficiency. Thus, iPSC-derived BMOs serve as a physiologically relevant in vitro model of the human BM microenvironment to study hematopoietic development and BM diseases.
3 April 2017 in Nature Genetics
Christoph Klein and colleagues identify loss-of-function mutations in SMARCD2 (BAF60b) that lead to neutropenia, specific granule deficiency and myelodysplasia. They show that SMARCD2 controls differentiation of myeloid–erythroid progenitor cells through interaction with CEBPɛ and that reduced SMARCD2 levels cause transcription and chromatin alterations in acute myeloid leukemia cells. We identify SMARCD2 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily D, member 2), also known as BAF60b (BRG1/Brahma-associated factor 60b), as a critical regulator of myeloid differentiation in humans, mice, and zebrafish. Studying patients from three unrelated pedigrees characterized by neutropenia, specific granule deficiency, myelodysplasia with excess of blast cells, and various developmental aberrations, we identified three homozygous loss-of-function mutations in SMARCD2. Using mice and zebrafish as model systems, we showed that SMARCD2 controls early steps in the differentiation of myeloid–erythroid progenitor cells. In vitro, SMARCD2 interacts with the transcription factor CEBPɛ and controls expression of neutrophil proteins stored in specific granules. Defective expression of SMARCD2 leads to transcriptional and chromatin changes in acute myeloid leukemia (AML) human promyelocytic cells. In summary, SMARCD2 is a key factor controlling myelopoiesis and is a potential tumor suppressor in leukemia.
1 March 2018 in Journal of Allergy and Clinical Immunology
17 April 2017 in Journal of Clinical Immunology
10 November 2026 in Blood Advances
Neutrophils are the most abundant circulating leukocytes in humans and act as key effectors of innate immunity. Severe congenital neutropenia (SCN) encompasses a heterogeneous group of disorders characterized by early onset of recurrent infections. Mutations in Jagunal homolog 1 (Jagn1) cause SCN, yet the mechanisms linking Jagn1 deficiency to defective neutrophil function and neutropenia remain unclear. Here, we identify Jagn1 as a critical regulator that connects intracellular protein trafficking and surface glycosylation during neutrophil development. Using neutrophils derived from Hoxb8-ER–immortalized progenitors, we show that Jagn1 expression is restricted to early progenitor stages and transcriptionally controlled by the transcription factor CCAAT/enhancer-binding protein α. Loss of Jagn1 delays neutrophil differentiation, resulting in progenitor accumulation. Functionally, Jagn1-deficient murine neutrophils exhibit defective E-selectin–dependent rolling and chemokine-induced adhesion in ex vivo and in vitro flow chambers, mirrored by impaired rolling, adhesion, and transmigration in vivo during tumor necrosis factor–induced inflammation. Mechanistically, lectin-binding and static adhesion assays revealed reduced sialylation of adhesion-relevant receptors on Jagn1-deficient neutrophils, leading to impaired E-selectin and CXCL8 binding. In addition, NLRP3-dependent S100A8/A9 release from Jagn1-deficient neutrophils was reduced after E-selectin stimulation. These findings define Jagn1 as a key determinant of neutrophil protein sialylation by regulating endoplasmic reticulum–Golgi posttranslational glycosylation, thereby ensuring proper sialylation of adhesion-relevant molecules, including E-selectin ligands and CXCR2. This mechanism provides a unifying explanation for the clinical and cellular phenotypes in Jagn1-associated SCN and may offer new therapeutic approaches in the treatment of patients with loss-of-function mutation in Jagn1.